nach oben

International Orthopaedics

Erschienen in:

01.01.2014 | Review Article

Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations

verfasst von: Plamen Kinov, Panayot P. Tanchev, Martin Ellis, Gershon Volpin

Erschienen in: International Orthopaedics | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

The risk of venous thromboembolism following major orthopaedic procedures, such as joint arthroplasty and hip fracture surgery, are well recognised and represent one of the major challenges in orthopaedic practice, having in mind the increasing number of arthroplasties of the hip and knee done worldwide per year and their successful outcome. This potentially fatal complication remains a challenge in orthopaedic practice. The percentage of patients in whom antithrombotic prophylaxis has not been administrated or has been inadequate may reach 50 %. Until recently, anticoagulant prophylaxis with low molecular weight heparins (LMWHs) has been a “gold standard”. LMWHs are indirect inhibitors of the clotting factors Xa and thrombin and are administered by daily subcutaneous injection. Their efficacy has been proven in numerous clinical trials and the rate of complications with their use is relatively low. However these compounds are associated with a failure rate and are inconvenient to administer, requiring subcutaneous injection, leading to inadequate compliance. For these reasons postoperative thrombembolism continues to occur in up to 10 % of this patient population. Recently, novel oral anticoagulants have been introduced into practice for thromboprophylaxis after joint arthroplasy and hip fracture surgery. These drugs are direct thrombin inhibitors (dabigatran) or direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban). These oral drugs have the same efficacy as the LMWHs with the same or slightly more clinically significant haemorrhage as their main side effect. Their ease of administration and favourable clinical profile makes them an important addition to the therapeutic armamentarium available for venous thromboprophylaxis. In this paper we review the aetiology and pathogenesis of venous thromboembolism and present the various alternatives for its prevention after major orthopaedic surgical procedures with emphasis on the new oral drugs.

Markovic-Denic L, Zivkovic K, Lesic A et al (2012) Risk factors and distribution of symptomatic venous thromboembolism in total hip and knee replacements: prospective study. Int Orthop 36(6):1299–1305PubMedCentralPubMedCrossRef

Geerts WH, Pineo GF, Heit JA et al (2004) Prevention of venous thromboembolism: the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:338S–400SPubMedCrossRef

American Academy of Orthopaedic Surgeons (2011) Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. Evidence based guidelines and evidence report

Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ (2012) Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(Suppl 2):7S–47SPubMedCrossRef

Hill J, Treasure T (2007) Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients having surgery: summary of NICE guidance. BMJ 334:1053–1054PubMedCrossRef

Nicolaides AN, Fareed J, Kakkar AK et al (2006) Prevention and treatment of venous thromboembolism. International consensus statement (Guidelines according to scientific evidence). Int Angiol 25:101–161

Cohen A, Bailey CS, Alikhan R, Cooper DJ (2001) Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty. Thromb Haemost 85:940–941PubMed

Cohen A, Quinlan D (2000) PEP trial. Lancet 356:247–248PubMedCrossRef

Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr (2003) Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the hip and knee register. Chest 124(Suppl 6):349S–356SPubMedCrossRef

10.

Friedman RJ, Gallus AS, Cushner FD, Fitzgerald G, Anderson FA Jr (2008) Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 24(1):87–97PubMed

11.

Trendelenburg F (1908) Ueber die operative Behandlung der Embolie der Lungenarterie. Arch Klin Chir 86:686–700

12.

Meyer JA (1990) Friedrich Trendelenburg and the surgical approach to massive pulmonary embolism. Arch Surg 125:1202–1205PubMedCrossRef

13.

Sautter RD, Lawton BR, Magin OE et al (1963) Pulmonary embolectomy: report of a case with preoperative and postoperative angiograms. N Eng J Med 269:997–999CrossRef

14.

Homans J (1934) Thrombosis of the deep veins of the lower leg, causing pulmonary embolism. N Engl J Med 211:993–997CrossRef

15.

Howell WH, Holt E (1918) Two new factors in blood coagulation—heparin and proantithrombin. Am J Physiol 47:328–333

16.

Craaford C (1937) Preliminary report on post-operative treatment with heparin as a preventive of thrombosis. Acta Chir Scand 79:407–426

17.

Murray GDW, Best CH (1938) Heparin and thrombosis: the present situation. JAMA 110:118–122CrossRef

18.

Sharnoff JG, Kass HH, Mistica BA (1962) A plan of heparinization of the surgical patient to prevent postoperative thromboembolism. Surg Gynecol Obstet 115:75–79PubMed

19.

Hirsh J, Bauer KA, Donati MB et al (2008) Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133(Suppl 6):141S–159SPubMedCrossRef

20.

Geerts WH, Heit JA, Clagett GP et al (2001) Prevention of venous thromboembolism. Chest 119(1):132S–175SPubMedCrossRef

21.

Eikelboom JW, Quinlan DJ, Douketis JD (2001) Extended duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358:9–15PubMedCrossRef

22.

Hull RD, Pineo GF, Stein PD et al (2001) Extended out of hospital low-molecular weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med 135:858–869PubMedCrossRef

23.

Allen EV, Hines EA, Kvale WF et al (1947) The use of dicumarol as an anticoagulant: experience in 2,307 cases. Ann Intern Med 27:371–381PubMedCrossRef

24.

Sevitt S, Gallagher NG (1959) Prevention of venous thrombosis and pulmonary embolism in injured patients. Lancet 2:981–989PubMedCrossRef

25.

Hull RD, Raskob G, Pineo G et al (1993) A comparison of subcutaneous low-molecular- weight heparin with warfarin sodium for prophylaxis against deep-vein-thrombosis after hip or knee implantation. N Engl J Med 329:1370–1376PubMedCrossRef

26.

O’Brien JR (1968) Effects of salicylates on human platelets. Lancet 2:779–783CrossRef

27.

Vulcano E, Gesell M, Esposito A et al (2012) Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol. Int Orthop 36(10):208–210CrossRef

28.

Westrich GH, Sculco TP (1996) Prophylaxis against deep venous thrombosis after total knee arthroplasty: pneumatic planter compression and aspirin compared with aspirin alone. J Bone Joint Surg Am 78:826–834PubMed

29.

Gent M, Hirsh J, Ginsberg JS et al (1996) Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 93:80–84PubMedCrossRef

30.

Pulmonary Embolism Prevention (PEP) trial Collaborative Group (2000) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary embolism prevention (PEP) trial. Lancet 355(9212):1295–1302CrossRef

31.

Anderson DR, Dunbar MJ, Bohm ER et al (2013) Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med 158(11):800–806PubMedCrossRef

32.

Clarggett GP, Anderson FA, Levine MN et al (1992) Prevention of venous thromboembolism. Chest 102:391S–407SCrossRef

33.

Тurpie AGG, Levine MN, Hirsh J et al (1986) A randomized trial of a low-molecular heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 315:925–929CrossRef

34.

Planes A, Vochelle N, Mazas F et al (1988) Prevention of postoperative venous thrombosis: a randomized trial comparing unfractioned heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 60:407–410PubMed

35.

Leclerc JR, Geerts WH, Desjardins L et al (1996) Prevention of venous thromboembolism after knee arthroplasty: a randomized, double-blind trial comparing enoxaparin with warfarin. Ann Intern Med 124:619–626PubMedCrossRef

36.

Lunceford EM, Patel SJ, Niestat HB et al (1978) Prevention of thrombophlebitis in total hip arhtoplasty by early ambulation. Clin Orthop 133:273

37.

Charalambous C, Cleanthous S, Tryfonidis M et al (2003) Foot pump prophylaxis for deep venous thrombosis-rate of effective usage following knee and hip arthroplasty. Int Orthop 27:208–210PubMedCentralPubMedCrossRef

38.

Hull R, Delmore TJ, Hirsh J et al (1979) Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery. Thromb Res 16:37–45PubMedCrossRef

39.

Haas SB, Insall JN, Scuderi GR, Windsor RE, Ghelman B (1990) Pneumatic sequential compression boots compared with aspirin prophylaxis of deep-vein thrombosis after total knee arthroplasty. J Bone Joint Surg Am 72:27–31PubMed

40.

Eriksson BI, Borris LC, Friedman RJ et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358(26):2765–2775PubMedCrossRef

41.

Kakkar AK, Brenner B, Dahl OE et al (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632):31–39PubMedCrossRef

42.

Lassen MR, Ageno W, Borris LC et al (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358(26):2776–2786PubMedCrossRef

43.

Turpie AGG, Lassen MR, Davidson BL et al (2009) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 373(9676):1673–1680PubMedCrossRef

44.

Dahl OE, Kurth AA, Rosencher N et al (2012) Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery. Int Orthop 36(4):741–748PubMedCentralPubMedCrossRef

45.

Eriksson BI, Dahl OE, Rosencher E et al (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5(11):2178–2185PubMedCrossRef

46.

Eriksson BI, Dahl OE, Rosencher N et al (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370(9591):949–956PubMedCrossRef

47.

Eriksson BI, Friedman R (2009) Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin Appl Thromb Hemost 15:25S–31SPubMedCrossRef

48.

Wolowacz SE, Roskel NS, Plumb JM, Caprini JA, Eriksson BI (2009) Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty: a meta-analysis. J Thromb Haemost 101(1):77–85

49.

Lassen MR, Raskob GE, Gallus A et al (2009) Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med 361(6):594–604PubMedCrossRef

50.

Lassen MR, Raskob GE, Gallus A et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 375(9717):807–815PubMedCrossRef

51.

Lassen MR, Gallus A, Raskob GE et al (2010) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363:2487–2498PubMedCrossRef

52.

Turpie AGG, Bauer KA, Eriksson BI, Lassen MR (2003) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopaedic surgery. Arch Intern Med 162:1833–1840CrossRef

53.

Pengo V, Lensing AWA, Prins MH et al (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 350(22):2257–2323PubMedCrossRef

54.

Spyropoulos AC, Lin J (2007) Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 13(6):475–486PubMed

Titel: Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations
verfasst von: Plamen Kinov
Panayot P. Tanchev
Martin Ellis
Gershon Volpin
Publikationsdatum: 01.01.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: International Orthopaedics / Ausgabe 1/2014
Print ISSN: 0341-2695
Elektronische ISSN: 1432-5195
DOI: https://doi.org/10.1007/s00264-013-2134-8

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Arthroskopie kann Knieprothese nicht hinauszögern

25.04.2024 Gonarthrose Nachrichten

Ein arthroskopischer Eingriff bei Kniearthrose macht im Hinblick darauf, ob und wann ein Gelenkersatz fällig wird, offenbar keinen Unterschied.

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Reactive oxygen species-mediated mitochondrial dysfunction plays a critical role in high glucose-induced nucleus pulposus cell injury

Erratum to: Design, operative technique and ten-year results of the Hermes™ patellofemoral arthroplasty

A selected screening programme was less effective in the detection of methicillin-resistant Staphylococcus aureus colonisation in an orthopaedic unit

Low-dose dexamethasone with levobupivacaine improves analgesia after supraclavicular brachial plexus blockade

Mechanical behaviour of low-cost dynamic compression plates correlates with manufacturing quality standards